Genscript Biotech Corporation (GNNSF)
OTCMKTS
· Delayed Price · Currency is USD
1.300
0.00 (0.00%)
Apr 23, 2025, 4:00 PM EDT
Genscript Biotech Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Net Income | 2,962 | -95.48 | -226.85 | -358.71 | -204.95 | Upgrade
|
| Depreciation & Amortization | 75.71 | 71.88 | 61.18 | 45.86 | 32.33 | Upgrade
|
| Other Amortization | 1.96 | 2.17 | 3.07 | 1.92 | 0.56 | Upgrade
|
| Loss (Gain) From Sale of Assets | 1.19 | 0.69 | 0.77 | 0.91 | 1.11 | Upgrade
|
| Asset Writedown & Restructuring Costs | 45.51 | 11.66 | 11.48 | - | 3.56 | Upgrade
|
| Loss (Gain) From Sale of Investments | 0.26 | -2.43 | 3.64 | -0.53 | -1.8 | Upgrade
|
| Loss (Gain) on Equity Investments | 39.07 | 1.38 | 0.03 | - | 0.6 | Upgrade
|
| Stock-Based Compensation | 76.52 | 60.59 | 65.15 | 39.69 | 17.64 | Upgrade
|
| Provision & Write-off of Bad Debts | 6.56 | 4.78 | 1.15 | 0.93 | -0.64 | Upgrade
|
| Other Operating Activities | -3,020 | 264.61 | -204.38 | -9.51 | 16.98 | Upgrade
|
| Change in Accounts Receivable | 95.46 | -116.99 | 38.07 | 1.57 | -69.91 | Upgrade
|
| Change in Inventory | -10.53 | -3.93 | -19.53 | -15.14 | -14.97 | Upgrade
|
| Change in Accounts Payable | 15.99 | -37.03 | 25.58 | 8.07 | 5.43 | Upgrade
|
| Change in Unearned Revenue | -35.75 | 100.77 | 6.76 | 3.54 | 31.48 | Upgrade
|
| Change in Other Net Operating Assets | 20.28 | -29.74 | 113.59 | 144.6 | 31.49 | Upgrade
|
| Operating Cash Flow | 75.65 | -286.91 | -120.29 | -136.79 | -151.09 | Upgrade
|
| Capital Expenditures | -195.79 | -252.45 | -216.11 | -133.04 | -121.88 | Upgrade
|
| Sale of Property, Plant & Equipment | 0.24 | 0.24 | 0.09 | 0.27 | 0.06 | Upgrade
|
| Sale (Purchase) of Intangibles | -1.24 | -4.05 | -2.27 | -4.35 | -5.87 | Upgrade
|
| Investment in Securities | -806 | -101.72 | -219.75 | -82.44 | 26.49 | Upgrade
|
| Other Investing Activities | -453.57 | 0.25 | -5.25 | 7.02 | 1.04 | Upgrade
|
| Investing Cash Flow | -1,456 | -357.73 | -443.3 | -212.55 | -100.17 | Upgrade
|
| Long-Term Debt Issued | 102.61 | 74.39 | 33.06 | 26.04 | 52.92 | Upgrade
|
| Total Debt Issued | 102.61 | 74.39 | 33.06 | 26.04 | 52.92 | Upgrade
|
| Long-Term Debt Repaid | -67.74 | -34.06 | -7.39 | -74.94 | -30.6 | Upgrade
|
| Total Debt Repaid | -67.74 | -34.06 | -7.39 | -74.94 | -30.6 | Upgrade
|
| Net Debt Issued (Repaid) | 34.86 | 40.33 | 25.67 | -48.89 | 22.33 | Upgrade
|
| Issuance of Common Stock | 13.49 | 17.65 | 228.13 | 951.23 | 459.56 | Upgrade
|
| Repurchase of Common Stock | - | - | - | - | -9.46 | Upgrade
|
| Other Financing Activities | 18.17 | 1,010 | 165.52 | -0.19 | -8.67 | Upgrade
|
| Financing Cash Flow | 66.52 | 1,068 | 419.32 | 902.14 | 624.2 | Upgrade
|
| Foreign Exchange Rate Adjustments | -0.22 | -1.22 | -12.7 | -0.89 | 3.72 | Upgrade
|
| Net Cash Flow | -1,314 | 422.4 | -156.97 | 551.91 | 376.66 | Upgrade
|
| Free Cash Flow | -120.14 | -539.36 | -336.41 | -269.83 | -272.97 | Upgrade
|
| Free Cash Flow Margin | -20.21% | -96.23% | -53.76% | -55.06% | -69.84% | Upgrade
|
| Free Cash Flow Per Share | -0.06 | -0.26 | -0.16 | -0.13 | -0.14 | Upgrade
|
| Cash Interest Paid | 4.68 | 3.19 | 2.04 | 1.58 | 1.33 | Upgrade
|
| Cash Income Tax Paid | 16.6 | 2.66 | -0.66 | 0.71 | -4.53 | Upgrade
|
| Levered Free Cash Flow | -48.48 | -305.28 | -342.98 | -176.43 | -224.26 | Upgrade
|
| Unlevered Free Cash Flow | -43.46 | -301.7 | -334.69 | -174.95 | -223.37 | Upgrade
|
| Change in Net Working Capital | 6.41 | 196.21 | -28.03 | -112.04 | 18.32 | Upgrade
|
Updated Mar 12, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.